Rhenium (186Re) obisbemeda is under clinical development by Plus Therapeutics and currently in Phase II for Squamous Cell Carcinoma. According to GlobalData, Phase II drugs for Squamous Cell Carcinoma does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Rhenium (186Re) obisbemeda LoA Report. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Likelihood of Approval and Phase Transition Success Rate Model - Rhenium (186Re) Obisbemeda in Squamous Cell Carcinoma

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Rhenium (186Re) obisbemeda overview

Rhenium (186Re) obisbemeda is under development for the treatment of recurrent glioblastoma multiforme, kaposi sarcoma, lung adenocarcinoma, squamous cell carcinoma, breast cancer, head and neck squamous cell carcinoma, head and neck cancer, triple-negative breast cancer (TNBC), leptomeningeal peritoneal carcinomatosis, liver cancer, lung cancer, melanoma, ovarian carcinomatosis and pediatric brain cancers including ependymoma and high-grade glioma. It is administered through intertumoral, intrathecal and intraperitoneal routes. The drug candidate comprises of N, N-bis (2-mercaptoethyl)-N',N'-diethylethylenediamine (BMEDA)-conjugated to a chelated rhenium nanoliposomes and is being developed based on rhenium nanoliposome (RNL) technology. The drug candidate was also under development for the treatment of pediatric diffuse intrinsic pontine glioma.

See Also:

Plus Therapeutics overview

Plus Therapeutics, formerly Cytori Therapeutics Inc is a developmental-stage pharmaceutical company, which focuses on the discovery, development, and manufacturing of complex and innovative treatments for patients with cancer and other life-threatening diseases. The company’s pipeline of candidate drug products includes Doceplus, a patented albumin-stabilized Pegylated liposomal formulation of docetaxel; Doxoplus, a complex, injectable, generic Pegylated liposomal formulation of doxorubicin; BMEDA-chelated rhenium nanoliposome (RNL); and a co-encapsulated, doxorubicin and rhenium nanoliposome (DRNL). It uses a proprietary nanotechnology platform to reformulate and improve conventional chemotherapeutics. Plus Therapeutics is headquartered in Irvine, Texas, the US.

For a complete picture of Rhenium (186Re) obisbemeda’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 16 July 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.